Pliant Therapeutics announced two poster presentations, including a late-breaker, were presented at the European Association for the Study of the Liver, EASL, International Liver Congress being held June 5-8, 2024. “We were pleased to share our latest data from our bexotegrast program in PSC including positive topline results from our Phase 2a INTEGRIS-PSC trial. These data represent the progress we continue to make in advancing this novel drug in fighting fibrotic liver disease. We look forward to presenting additional data from INTEGRIS-PSC in the coming weeks,” said Eric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
- Pliant Therapeutics management to meet with Piper Sandler
- Pliant Therapeutics announces results from Phase 2a trial of bexotegrast
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis